| Literature DB >> 34236804 |
Marcus Taylor1, June Low1, Denish Apparau1, Vipin Mehta1, Rajamiyer Venkateswaran1.
Abstract
OBJECTIVE: Isolated aortic valve replacement is a safe and frequently performed cardiac surgical procedure. Although minimal access approaches including right anterior thoracotomy and partial sternotomy have been adopted by some surgeons in recent years, concerns about additional procedural morbidity and mortality during the early phase of the learning curve persist. The aim of this study was to assess the impact of the learning curve on outcomes for a single surgeon implementing a new minimal access aortic valve replacement service.Entities:
Keywords: Aortic Valve Prosthesis; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Learning Curve; Sternotomy
Mesh:
Year: 2021 PMID: 34236804 PMCID: PMC8597605 DOI: 10.21470/1678-9741-2020-0436
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Patient characteristics.
| Variable | Group 1 | Group 2 | Group | Total | |
|---|---|---|---|---|---|
| Age (mean±SD) | 74.3 (±7.9) | 69.9 (±13.2) | 69.0 (±12.8) | 0.163 | 71.0 (±11.7) |
| Age >75 years | 45.2% (n=14) | 35.5% (n=11) | 35.45% (n=11) | 0.665 | 38.7% (n=36) |
| Male sex | 41.9% (n=13) | 54.8% (n=17) | 54.8% (n=17) | 0.502 | 50.5% (n=47) |
| Diabetes mellitus | 22.6% (n=7) | 22.6% (n=7) | 6.5% (n=2) | 0.151 | 17.2% (n=16) |
| Hypertension | 71.0% (n=22) | 64.5% (n=20) | 74.2% (n=23) | 0.699 | 69.9% (n=65) |
| CVD | 12.9% (n=4) | 9.7% (n=3) | 3.2% (n=1) | 0.384 | 8.6% (n=8) |
| PVD | 9.7% (n=3) | 9.7% (n=3) | 0% (n=0) | 0.201 | 6.5% (n=6) |
| COPD | 9.7% (n=3) | 16.1% (n=5) | 19.4% (n=6) | 0.055 | 15.1% (n=14) |
| Redo | 0% (n=0) | 6.5% (n=2) | 0% (n=0) | 0.130 | 2.2% (n=2) |
| History of AF | 19.4% (n=6) | 22.6% (n=7) | 6.5% (n=2) | 0.188 | 16.1% (n=15) |
| NYHA ≥3 | 51.6% (n=16) | 51.6% (n=16) | 51.6% (n=16) | 1 | 51.6% (n=48) |
| CKD | 6.5% (n=2) | 9.7% (n=3) | 0% (n=0) | 0.228 | 5.4% (n=5) |
| LV dysfunction | 12.9% (n=4) | 12.9% (n=4) | 12.9% (n=4) | 1 | 12.9% (n=12) |
| Logistic EuroSCORE | 6.6% (IQR 4.5-9.5%) | 4.8% (IQR 2.7-9.5%) | 4.8% (IQR 2.5-7.2%) | 0.091 | 5.5% (IQR 3.2-8.0%) |
| Urgent operation | 12.90% (n=4) | 9.7% (n=3) | 16.1% (n=5) | 0.750 | 12.9% (n=12) |
Defined as left ventricular ejection fraction <50%.
Defined as patients requiring surgery during the same hospital admission.
AF=atrial fibrillation; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; CVD=cerebrovascular disease; IQR=interquartile range; LV=left ventricle; NYHA=New York Heart Association; PVD=peripheral vascular disease; SD=standard deviation
Intra-operative characteristics.
| Variable | Group 1 | Group 2 | Group 3 | Total | |
|---|---|---|---|---|---|
| CPB time (mean±SD) | 108.6 mins (± 18.8) | 102.1 mins (± 15.5) | 92.3 mins (± 19.5) | <0.001 | 101.0 mins (± 19.0) |
| Cross-clamp time (mean±SD) | 86.7 mins (±17.2) | 79.3 mins (±10.9) | 74.9 mins (±8.8) | 0.004 | 80.3 mins (±13.6) |
| Femoral vein cannulation | 87.1% (n=27) | 74.2% (n=23) | 3.2% (n=1) | <0.001 | 54.8% (n=51) |
| Right atrial cannulation | 12.9% (n=4) | 25.8% (n=8) | 38.7% (n=12) | 0.067 | 21.5% (n=24) |
| SVC cannulation | 0% (n=0) | 0% (n=0) | 58.1% (n=18) | <0.001 | 19.4% (n=18) |
| Conversion to full sternotomy | 9.7% (n=3) | 6.5% (n=2) | 3.3% (n=1) | 0.586 | 6.5% (n=6) |
CPB=cardiopulmonary bypass; SD=standard deviation; SVC=superior vena cava
Fig. 1Trend of cardiopulmonary bypass times over time.
Fig. 2Trend of cross-clamp times over time
Post-operative outcomes.
| Variable | Group 1 | Group 2 | Group 3 | Total | |
|---|---|---|---|---|---|
| In-hospital mortality | 0% (n=0) | 3.2% (n=1) | 3.2% (n=1) | 0.600 | 2.2% (n=2) |
| Re-exploration | 0% (n=0) | 0% (n=0) | 3.2% (n=1) | 0.364 | 1.1% (n=1) |
| Critical care re-admission | 0% (n=0) | 0% (n=0) | 6.5% (n=2) | 0.130 | 2.2% (n=2) |
| Need for blood transfusion | 12.9% (n=4) | 22.6% (n=7) | 25.8% (n=8) | 0.423 | 20.4% (n=19) |
| POAF | 41.9% (n=13) | 32.3% (n=10) | 16.1% (n=5) | 0.082 | 30.1% (n=28) |
| PPM implantation | 9.7% (n=3) | 0% (n=0) | 6.5% (n=2) | 0.228 | 5.4% (n=5) |
| Superficial wound infection | 3.2% (n=1) | 6.5% (n=2) | 0% (n=0) | 0.356 | 3.2% (n=3) |
| LRTI | 6.5% (n=2) | 9.7% (n=3) | 9.7% (n=3) | 0.872 | 8.6% (n=8) |
| Paravalvular leak | 3.2% (n=1) | 3.2% (n=1) | 0% (n=0) | 0.600 | 2.2% (n=2) |
| PLOS (median and IQR) | 7 days (IQR 7-12) | 6 days (IQR 5-9) | 6 days (IQR 5-10) | 0.102 | 7 days (IQR 5-10) |
| Technical failure | 16.1% (n=5) | 16.1% (n=5) | 6.5% (n=2) | 0.423 | 12.9% (n=12) |
IQR=interquartile range; LRTI=lower respiratory tract infection; PLOS=post-operative length of stay; POAF=post-operative atrial fibrillation; PPM=permanent pacemaker
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ANOVA | = Analysis of variance | PS | = Partial sternotomy | |
| AVR | = Aortic valve replacement | PVL | = Paravalvular leak | |
| CUSUM | = Cumulative sum | RAT | = Right anterior thoracotomy | |
| CPB | = Cardiopulmonary bypass | RIMA | = Right internal mammary artery | |
| IQR | = Interquartile range | SD | = Standard deviation | |
| LRTI | = Lower respiratory tract infection | SPSS | = Statistical Package for the Social Sciences | |
| PLOS | = Post-operative length of stay | SVC | = Superior vena cava | |
| POAF | = Post-operative atrial fibrillation | TOE | = Transoesophageal echo | |
| PPM | = Permanent pacemaker | |||
| Authors' roles & responsibilities | |
|---|---|
| MT | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| JL | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| DA | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
| VM | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
| RV | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |